The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV

AIDS

Volumn 22, Issue 15, 2008, Pages 2025-2033

  Schackman, Bruce R ^a   Scott, Callie A ^b   Walensky, Rochelle P ^b,c,d   Losina, Elena ^b,c,d,e   Freedberg, Kenneth A ^b,c,d   Sax, Paul E ^c,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Abacavir; Antiretroviral therapy; Cost effectiveness; Genetic testing; HIV

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR; HLA B ANTIGEN; HLA B5701 ANTIGEN; LAMIVUDINE PLUS ZIDOVUDINE; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DNA SCREENING; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENETIC SCREENING; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT PLANNING; UNITED STATES; VIROLOGY; VIRUS INHIBITION; VIRUS MUTATION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DIDEOXYNUCLEOSIDES; DRUG COSTS; DRUG HYPERSENSITIVITY; FEMALE; GENETIC SCREENING; HEALTH CARE COSTS; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACOGENETICS; PHOSPHONIC ACIDS; QUALITY-ADJUSTED LIFE YEARS; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 53549095195     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283103ce6     Document Type: Article

References (34)

1. Castillo SA, Hernandez JE, Brothers CH. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. Drug Saf 2006; 29:811-826.
2. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
3. Hetherington S, Hughes AR, MostellerM, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122.
4. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43:99-102.
5. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
6. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. [Accessed 5 March 2008].
7. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831.
8. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990-997.
9. Yeni P, Sutherland-Phillips D, Wannamaker P, Hernandez J, Brothers C, Yau L, et al. Reported incidence and severity of suspected abacavir hypersensitivity reactions (HSR) through at least 6 weeks in a large, controlled clinical trial using a once-daily (OAD) abacavir 600 mg/lamivudine 300 mg tablet (ABC/ 3TC FDC) dual nucleoside backbone with a boosted protease inhibitor: the KLEAN study [abstract TuPe2.4C08]. 3rd IAS Conference on HIV Pathogenesis, Treatment and Prevention; 24-27 July 2005; Rio de Janeiro, Brazil.
10. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
11. Dodek P, Phillips P. Questionable history of immediate-type hypersensitivity to penicillin in Staphylococcal endocarditis: treatment based on skin-test results versus empirical alternative treatment - a decision analysis. Clin Infect Dis 1999; 29:1251-1256.
12. Pepper PV, Owens DK. Cost-effectiveness of the pneumococcal vaccine in healthy younger adults. Med Decis Making 2002; 22:S45-S57.
13. Johnson MA, Gathe JC Jr, Podzamczer D, Molina JM, Naylor CT, Chiu YL, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43:153-160.
14. Arribas J, Pozniak AL, Gallant JE, DeJesus E, Campo RE, Chen SS, et al. Three-year safety and efficacy of emtricitabine (FTC)/ tenofovir DF (TDF) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (AZT/3TC) and EFV in antiretroviral treatment-naïve patients [abstract WEPEB029]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia.
15. Laboratory Corporation of America. HLA-B5701 Test, http:/www.labcorp.com/ datasets/labcorp/html/chapter/mono/h1002200.htm. [Accessed 5 March 2008]; 2007.
16. Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule. http://www.cms.hhs.gov/ClinicalLab-FeeSched/01_overview.asp. [Accessed 5 March 2008]; 2006.
17. Red book. Montvale, NJ: Thomson PDR; 2006.
18. Centers for Medicare and Medicaid Services. Medicare Physician Fee Schedule. http://www.cms.hhs.gov/Physician-FeeSched/01_Overview.asp#TopOfPage. [Accessed 5 March 2008]; 2006.
19. Cong ME, Heneine W, Carcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81:3037-3041.
20. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 2006; 43:103-105.
21. Losina E, Schackman BR, Sadownik S, Gebo KA, Walensky RP, Weinstein MC, et al. Disparities in survival attributable to suboptimal HIV care in the US: Influence of gender and race/ethnicity [abstract 142]. 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California.
22. Allele frequencies in worldwide populations, www.allelefre-quencies.net. [Accessed 5 March 2008].
23. SaagM, Balu R, Brachman P, Brothers C, Stancil B, Mosteller M, et al. High sensitivity of HLA-B*5701 in whites and blacks in immunologically confirmed cases of abacavir hypersensitivity (ABC HSR) [abstract WEAB305]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25 2007; Sydney, Australia.
24. NIAID, NIH. NIAID Modifies HIV Antiretroviral Treatment Study: Combination Therapy that Includes ABC/3TC Found Less Effective in Subgroup of Antiretroviral-Naïve Individuals, http://www3.niaid.nih.gov/news/ newsreleases/2008/actg5202bulle-tin.htm. 28 Febraury 2008.
25. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286:2270-2279.
26. Ma Q, Brazeau D, Forrest A, Morse GD. Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics 2007; 8:1169-1178.
27. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmo-hamed M. Cost-effectiveness analysis of HLAB*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335-342.
28. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
29. Smith K, Fine D, Patel P, Bellos N, Sloan L, Lackey P, et al. Efficacy and safety of abacavir/lamivudine compared to tenofovir/ emtricitabine in combination with once-daily lopinavir/ ritonavir through 48 weeks in the HEAT study [abstract 774]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts.
30. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller ME), et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
31. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term nonpresenter. AIDS 2001; 15:77-85.
32. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
33. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45:1-3.
34. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540.